Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia
Helen B. Pearson, Pedro A. Perez-Mancera, Lukas E. Dow, Andrew Ryan, Pierre Tennstedt, Debora Bogani, Imogen Elsum, Andy Greenfield, David A. Tuveson, Ronald Simon, Patrick O. Humbert
Helen B. Pearson, Pedro A. Perez-Mancera, Lukas E. Dow, Andrew Ryan, Pierre Tennstedt, Debora Bogani, Imogen Elsum, Andy Greenfield, David A. Tuveson, Ronald Simon, Patrick O. Humbert
View: Text | PDF
Research Article Oncology

SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia

  • Text
  • PDF
Abstract

Loss of cellular polarity is a hallmark of epithelial cancers, raising the possibility that regulators of polarity have a role in suppressing tumorigenesis. The Scribble complex is one of at least three interacting protein complexes that have a critical role in establishing and maintaining epithelial polarity. In human colorectal, breast, and endometrial cancers, expression of the Scribble complex member SCRIB is often mislocalized and deregulated. Here, we report that Scrib is indispensable for prostate homeostasis in mice. Scrib heterozygosity initiated prostate hyperplasia, while targeted biallelic Scrib loss predisposed mice to prostate intraepithelial neoplasia. Mechanistically, Scrib was shown to negatively regulate the MAPK cascade to suppress tumorigenesis. Further analysis revealed that prostate-specific loss of Scrib in mice combined with expression of an oncogenic Kras mutation promoted the progression of prostate cancer that recapitulated the human disease. The clinical significance of the work in mice was highlighted by our observation that SCRIB deregulation strongly correlated with poor survival in human prostate cancer. These data suggest that the polarity network could provide a new avenue for therapeutic intervention.

Authors

Helen B. Pearson, Pedro A. Perez-Mancera, Lukas E. Dow, Andrew Ryan, Pierre Tennstedt, Debora Bogani, Imogen Elsum, Andy Greenfield, David A. Tuveson, Ronald Simon, Patrick O. Humbert

×

Figure 4

Biallelic Scrib loss causes prostate neoplasia.

Options: View larger image (or click on image) Download as PowerPoint
Biallelic Scrib loss causes prostate neoplasia.
   
(A) Scrib mRNA is de...
(A) Scrib mRNA is decreased in PBCre+;Scrib+/fl (45.2%) and PBCre+;Scribfl/fl (14.5%) compared with PBCre+ prostates at 400 days. (B) Scrib IF shows reduced Scrib expression in PBCre+;Scribfl/fl prostate epithelium (400 days). (C) Representative H&E images of PBCre+, PBCre+;Scrib+/fl, and PBCre+;Scribfl/fl prostates (400 days). (D) Prostate phenotype incidence at 100, 200, and 400 days (n ≥ 10). (E) PCNA IHC shows a significant increase in the number of PCNA-positive cells in PBCre+;Scribfl/fl mice (4.0% ± 0.24%) compared with PBCre+;Scrib+/fl (2.1% ± 0.82%) and PBCre+ mice (0.6% ± 0.38%) at 400 days. (F) p-ERK staining revealed a significant increase in MAPK signaling in PBCre+;Scrib+/fl (7.1% ± 1.64%) and PBCre+;Scribfl/fl mice (13.1% ± 4.18%) compared with PBCre+ controls (1.8% ± 0.58%) at 400 days. (G) p-ELK1 staining shows a significant increase in p-ELK1 expression in PBCre+;Scrib+/fl (1.8% ± 0.25%) and PBCre+;Scribfl/fl (4.2% ± 1.67%) compared with WT tissue (0.4% ± 0.13%) at 400 days. Arrows indicate positive nuclei. Scale bars: 50 μm (larger panels) and 10 μm (insets). Data are mean ± SD; n = 3; P values represent unpaired t test. Error bars indicate SD.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts